• NICE nod for breast cancer delay drug pharmatimes
    April 02, 2019
    The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for NHS use within the Cancer Drugs Fund (CDF).
PharmaSources Customer Service